Lazertinib (Leclaza) 80mg | Yuhan Korea Originator | GLT

REQUEST A QUOTE

Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.

  • We reply within 24 hours with pricing, availability & COA
  • Serves individuals and institutions worldwide

Prefer email? [email protected] · +86 15234153837

Share
Product description

Generic Information: Leclaza (South Korea)

Leclaza is the original South Korean brand of lazertinib, developed by Yuhan Corporation from a candidate molecule acquired from Genosco and later licensed to Johnson & Johnson for worldwide development. Hailed at home as a landmark of Korean drug innovation — and recognised with a Best Pharmaceutical Product award at the first Prix Galien Asia — Leclaza supplies eighty 80 mg tablets per pack and remains the reference presentation of the molecule in its birth market.

What Is Lazertinib (Leclaza) Used For?

Leclaza was first approved in Korea for lung cancers that had progressed after earlier EGFR inhibitors because of the T790M resistance mutation, then extended to untreated advanced disease. Today its principal use is alongside amivantamab as a first-line option for EGFR exon 19 deletion or L858R mutated non-small cell lung cancer, a combination that has earned approvals across the United States, Europe, Japan and China in addition to Korea.

How Does Lazertinib Work?

The molecule is engineered to shut off two disease-driving EGFR states — the original sensitising mutation and the T790M escape mutation — by forming a permanent chemical bond with the receptor's catalytic site. Normal EGFR function in skin and the digestive tract is largely left intact, which reduces the acne-like toxicity typical of first-generation drugs. Activity inside the central nervous system adds a defensive line against metastases that seed the brain.

Indications

Clinically, Leclaza serves EGFR-mutated NSCLC patients in two settings: after progression on an earlier EGFR inhibitor where T790M is present, and — more commonly now — as the oral component of first-line doublet therapy with amivantamab. Candidates undergo molecular profiling before treatment, and managing physicians weigh history of interstitial lung disease, cardiac conduction and clotting risk when planning the regimen.

Dosage

Standard dosing is 240 mg once daily by mouth irrespective of meals; tablets are swallowed intact and never divided. Twenty-four-hour coverage means the Korean 84-tablet pack conveniently matches a four-week cycle at three 80 mg tablets per day, aligning with amivantamab infusion visits. A forgotten dose is taken when noticed unless the next tablet is due within twelve hours, in which case it is skipped entirely.

Side Effects

Observed effects cluster around the skin and digestive tract: acneiform rash, nail inflammation, itching, stomatitis, diarrhoea and appetite loss, plus tiredness and aching muscles or joints. Blood tests commonly reveal reduced thyroid hormone or magnesium. Regimens that add amivantamab inherit that antibody's own risks — infusion reactions, venous thromboembolism and interstitial lung changes — so patients receive structured education on warning symptoms before the first cycle.

Storage

Leclaza tablets require only ordinary room-temperature storage in their sealed original packaging, away from humidity — refrigeration is unnecessary. Ambient-condition courier transport from GLT's Hong Kong-licensed facility preserves product quality end to end, with batch documentation enclosed in every shipment.

Why Choose Leclaza Through GLT?

Buying the Korean originator presentation connects patients and institutions to the very batch lineage that pioneered this molecule — Yuhan-manufactured Leclaza with Korean regulatory provenance, dispatched by GLT with traceable sourcing papers. For procurement teams benchmarking multiple presentations of lazertinib, GLT lists the US, China and Korea originator packs and the Laos generic side by side for transparent comparison.

How to Order

To order Leclaza (lazertinib) from GLT, reach us on WhatsApp at +86 15234153837 or by email at [email protected] — we confirm pack availability, delivery cost and timing to your country, and ship from a Hong Kong-licensed facility.

FAQ

Who makes Leclaza? Yuhan Corporation of South Korea developed and manufactures Leclaza; Johnson & Johnson's Janssen holds ex-Korea commercialisation rights under the Lazcluze name.

Why is the Korean pack 84 tablets? At the standard daily dose of three 80 mg tablets, an 84-tablet pack covers exactly 28 days of therapy.

Is Leclaza an original or a copy? It is the originator — the first lazertinib product ever approved (Korea, 2021), developed by Yuhan from the Genosco candidate molecule.

Related Oncology Products

Orforglipron (OriYo) 0.8–17.2mg Tablets | Bangladesh Generic Oral GLP-1 | GLT

National Drug Co. generic orforglipron, 6-dose titration for weight management

Tirzema (Tirzepatide) 2.5/5/7.5mg/0.5mL Single-Dose Pen | Incepta Bangladesh | GLT

Tirzema — Incepta Pharmaceuticals tirzepatide single-dose pen, three official strengths (2.5/5/7.5mg/0.5mL) for T2DM and weight...

KangQuXin 康曲欣 (Avatrombopag) 20mg*10 Tablets | Beijing Continent Gyre | GLT

KangQuXin — avatrombopag by Beijing Continent Pharmaceutical (Gyre Therapeutics, Nasdaq: GYRE), China Mainland

Olumiant (Baricitinib) 2mg/4mg Tablets | JAK1/JAK2 Inhibitor | Eli Lilly USA | GLT

Eli Lilly's selective JAK1/JAK2 inhibitor for rheumatoid arthritis, atopic dermatitis and severe alopecia areata.

Palutini (Baricitinib) 4mg | Generic JAK1/JAK2 Inhibitor | Trans Continental Life Science & Pharmaceuticals (TLPH) | GLT

Generic baricitinib (JAK1/JAK2 inhibitor) by Trans Continental Life Science & Pharmaceuticals (TLPH) (Laos) — an...

LuciAvat (Avatrombopag) 20mg*28 Tablets | Lucius Pharmaceuticals Laos | GLT

LuciAvat — avatrombopag 20mg (23.6mg maleate) film-coated tablets by Lucius Pharmaceuticals (Lao) Co., Ltd., Vientiane

XinKePing 欣可平 (Avatrombopag) 20mg*10 Tablets | Nanjing Hencer China | GLT

XinKePing — API-plus-tablet integrated avatrombopag from Nanjing Hencer Pharmaceutical (Jemcare group), China Mainland

Rizonib (Crizotinib) 250mg Capsules | DIL Bangladesh Generic Xalkori for ALK+ NSCLC | GLT

Rizonib 250 by Drug International Ltd (DIL), Tongi Gazipur — affordable crizotinib generic from Bangladesh